Estimating the Clinical and Economic Impact of Introducing a New Antibacterial into Greek Clinical Practice for the Management of Hospital-Acquired Infections with Limited Treatment Options-Reference-Cited by-同舟云学术

Estimating the Clinical and Economic Impact of Introducing a New Antibacterial into Greek Clinical Practice for the Management of Hospital-Acquired Infections with Limited Treatment Options

Published:2022-12-21 Issue:2 Volume:12 Page:527-543
ISSN:2193-8229
Container-title:Infectious Diseases and Therapy
language:en
Short-container-title:Infect Dis Ther

Author:

Barmpouni Myrto,Gordon Jason P.,Miller Ryan L.,Pritchard Clive R. J.,Dennis James W.,Grammelis Vassilis,Rousakis Aris,Souliotis Kyriakos,Poulakou Garyphallia,Daikos George L.,Al-Taie Amer^ORCID

Funder

Pfizer Greece

Publisher

Springer Science and Business Media LLC

Subject

Infectious Diseases,Microbiology (medical)

Link

https://link.springer.com/content/pdf/10.1007/s40121-022-00743-4.pdf

Reference44 articles.

1. European Commission. A European One Health Action Plan against Antimicrobial Resistance (AMR). 2017. https://health.ec.europa.eu/system/files/2020-01/amr_2017_action-plan_0.pdf. Accessed 17 Oct.

2. Kritsotakis EI, Kontopidou F, Astrinaki E, Roumbelaki M, Ioannidou E, Gikas A. Prevalence, incidence burden, and clinical impact of healthcare-associated infections and antimicrobial resistance: a national prevalent cohort study in acute care hospitals in Greece. Infect Drug Resist. 2017;10:317–28.

3. Suetens C, Latour K, Kärki T, et al. Prevalence of healthcare-associated infections, estimated incidence and composite antimicrobial resistance index in acute care hospitals and long-term care facilities: results from two European point prevalence surveys, 2016 to 2017. Euro Surveill. 2018;23(46):1800516.

4. Albiger B, Glasner C, Struelens MJ, Grundmann H, Monnet DL, European Survey of Carbapenemase-Producing Enterobacteriaceae (EuSCAPE) working group. Carbapenemase-producing Enterobacteriaceae in Europe: assessment by national experts from 38 countries, May 2015. Euro Surveill. 2015;20(45):30062.

5. Cassini A, Högberg LD, Plachouras D, et al. Attributable deaths and disability-adjusted life-years caused by infections with antibiotic-resistant bacteria in the EU and the European Economic Area in 2015: a population-level modelling analysis. Lancet Infect Dis. 2019;19(1):56–66.

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Healthcare-associated infections in the intensive care unit;Medicinski podmladak;2024

2. Value assessment of antimicrobials using the STEDI framework – How steady is the outcome?;Health Policy;2023-10

3. Clinical and Economic Value of Reducing Antimicrobial Resistance in the Management of Hospital-Acquired Infections with Limited Treatment Options in Greece;Infectious Diseases and Therapy;2023-07

4. Quantifying the Economic and Clinical Value of Reducing Antimicrobial Resistance in Gram-negative Pathogens Causing Hospital-Acquired Infections in Australia;Infectious Diseases and Therapy;2023-06-21